Track GeoVax Labs, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

GeoVax Labs, Inc. GOVX Open GeoVax Labs, Inc. in new tab

1.33 USD
EPS
-31.75
P/B
0.32
ROE
-377.44
Beta
3.81
Target Price
270.83 USD
GeoVax Labs, Inc. logo

GeoVax Labs, Inc.

🧾 Earnings Recap – Q3 2025

GeoVax reports strong advancements in Q3 2025 across its vaccine portfolio, notably with promising regulatory guidance for its GEO-MVA vaccine, positioning the company for expedited market entry.

  • GEO-MVA vaccine candidate receives expedited development path from EMA, allowing direct progression to Phase III trials.
  • Initiated clinical batch preparation for GEO-MVA, with vaccine availability expected early next year for evaluation and potential stockpile needs.
  • Continued progress and recognition of GEO-CM04S1 as a vital solution for immunocompromised populations, supported by recent clinical presentations enhancing collaboration opportunities.
  • Ongoing discussions with government and international health organizations highlight the strategic importance of U.S.-based vaccine supply chains.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateApril 29, 2026
EPS-31.75
Book Value4.13
Price to Book0.32
% Insiders0.159%
Growth
Revenue Growth1.84%
Estimates
Forward P/E-1.55
Forward EPS-0.86
Target Mean Price270.83

DCF Valuation

Tweak assumptions to recompute fair value for GeoVax Labs, Inc. (GOVX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

GeoVax Labs, Inc. Logo GeoVax Labs, Inc. Analysis (GOVX)

United States Health Care Official Website Stock

Is GeoVax Labs, Inc. a good investment? GeoVax Labs, Inc. (GOVX) is currently trading at 1.33 USD. Market analysts have a consensus price target of 270.83 USD. This suggests a potential upside from current levels.

Earnings Schedule: GeoVax Labs, Inc. is expected to release its next earnings report on April 29, 2026. The market consensus estimate for Forward EPS is -0.86.

Investor FAQ

Does GeoVax Labs, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is GeoVax Labs, Inc.?

GeoVax Labs, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 29, 2026. The company currently has a trailing EPS of -31.75.

Company Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Exchange Ticker
NMS (United States) GOVX

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Jan. 31, 2024 0.070000
Jan. 12, 2026 0.040000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion